Open Access
Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy
2
German Cancer Consortium (DKTK), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany
|
Publication type: Journal Article
Publication date: 2019-07-29
PubMed ID:
31362406
Drug Discovery
Pharmaceutical Science
Molecular Medicine
Abstract
As the first radiopharmaceutical for Peptide Receptor Radionuclide Therapy (PRRT), Lutathera® was approved by the EMA in 2017 and the FDA in 2018 for the treatment of somatostatin receptor (SSTR) positive gastroenteropancreatic neuroendocrine tumors. Using the concept of PRRT, Lutathera® combines the radionuclide 177Lu with the somatostatin analogue DOTA-TATE, thus delivering ionizing radiation specifically to tumor cells expressing somatostatin receptors. As a result, DNA single- and double-strand breaks are provoked, in case of double-strand breaks leading to cell death of the tumor and its SSTR-positive lesions.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
5
10
15
20
|
|
|
Cancers
20 publications, 5.76%
|
|
|
Pharmaceuticals
16 publications, 4.61%
|
|
|
Pharmaceutics
15 publications, 4.32%
|
|
|
Journal of Medicinal Chemistry
14 publications, 4.03%
|
|
|
International Journal of Molecular Sciences
11 publications, 3.17%
|
|
|
Journal of Nuclear Medicine
7 publications, 2.02%
|
|
|
European Journal of Nuclear Medicine and Molecular Imaging
7 publications, 2.02%
|
|
|
EJNMMI Radiopharmacy and Chemistry
7 publications, 2.02%
|
|
|
Frontiers in Medicine
6 publications, 1.73%
|
|
|
EJNMMI Research
6 publications, 1.73%
|
|
|
Molecules
5 publications, 1.44%
|
|
|
Applied Radiation and Isotopes
5 publications, 1.44%
|
|
|
Bioconjugate Chemistry
4 publications, 1.15%
|
|
|
Frontiers in Oncology
4 publications, 1.15%
|
|
|
Acta Pharmaceutica Sinica B
4 publications, 1.15%
|
|
|
European Journal of Medicinal Chemistry
4 publications, 1.15%
|
|
|
Medical Physics
4 publications, 1.15%
|
|
|
Journal of Neuroendocrinology
4 publications, 1.15%
|
|
|
Chemical Science
4 publications, 1.15%
|
|
|
Frontiers in Nuclear Medicine
3 publications, 0.86%
|
|
|
Nuclear Medicine Communications
3 publications, 0.86%
|
|
|
Clinical Nuclear Medicine
3 publications, 0.86%
|
|
|
Frontiers in Pharmacology
3 publications, 0.86%
|
|
|
Frontiers in Endocrinology
3 publications, 0.86%
|
|
|
Nuclear Medicine and Biology
3 publications, 0.86%
|
|
|
Chinese Chemical Letters
3 publications, 0.86%
|
|
|
ChemMedChem
3 publications, 0.86%
|
|
|
Molecular Pharmaceutics
3 publications, 0.86%
|
|
|
Current Radiopharmaceuticals
2 publications, 0.58%
|
|
|
5
10
15
20
|
Publishers
|
10
20
30
40
50
60
70
80
|
|
|
MDPI
77 publications, 22.19%
|
|
|
Elsevier
55 publications, 15.85%
|
|
|
Springer Nature
52 publications, 14.99%
|
|
|
American Chemical Society (ACS)
31 publications, 8.93%
|
|
|
Wiley
28 publications, 8.07%
|
|
|
Frontiers Media S.A.
22 publications, 6.34%
|
|
|
Royal Society of Chemistry (RSC)
11 publications, 3.17%
|
|
|
Taylor & Francis
9 publications, 2.59%
|
|
|
Society of Nuclear Medicine
9 publications, 2.59%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
9 publications, 2.59%
|
|
|
Georg Thieme Verlag KG
5 publications, 1.44%
|
|
|
Bentham Science Publishers Ltd.
4 publications, 1.15%
|
|
|
Cold Spring Harbor Laboratory
3 publications, 0.86%
|
|
|
The Endocrine Society
2 publications, 0.58%
|
|
|
Pleiades Publishing
2 publications, 0.58%
|
|
|
American Association for Cancer Research (AACR)
2 publications, 0.58%
|
|
|
American Society of Clinical Oncology (ASCO)
2 publications, 0.58%
|
|
|
American Scientific Publishers
1 publication, 0.29%
|
|
|
Mary Ann Liebert
1 publication, 0.29%
|
|
|
Spandidos Publications
1 publication, 0.29%
|
|
|
Japanese Society of Radiological Technology
1 publication, 0.29%
|
|
|
The Society of Synthetic Organic Chemistry, Japan
1 publication, 0.29%
|
|
|
American Association for the Advancement of Science (AAAS)
1 publication, 0.29%
|
|
|
Oxford University Press
1 publication, 0.29%
|
|
|
Walter de Gruyter
1 publication, 0.29%
|
|
|
Korean Pancreatobiliary Association
1 publication, 0.29%
|
|
|
MedCrave Group Kft.
1 publication, 0.29%
|
|
|
SCEEMP
1 publication, 0.29%
|
|
|
OOO Zhurnal "Mendeleevskie Soobshcheniya"
1 publication, 0.29%
|
|
|
10
20
30
40
50
60
70
80
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
347
Total citations:
347
Citations from 2025:
86
(24.79%)
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Hennrich U., Kopka K. Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy // Pharmaceuticals. 2019. Vol. 12. No. 3. p. 114.
GOST all authors (up to 50)
Copy
Hennrich U., Kopka K. Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy // Pharmaceuticals. 2019. Vol. 12. No. 3. p. 114.
Cite this
RIS
Copy
TY - JOUR
DO - 10.3390/ph12030114
UR - https://doi.org/10.3390/ph12030114
TI - Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy
T2 - Pharmaceuticals
AU - Hennrich, Ute
AU - Kopka, K.
PY - 2019
DA - 2019/07/29
PB - MDPI
SP - 114
IS - 3
VL - 12
PMID - 31362406
SN - 1424-8247
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2019_Hennrich,
author = {Ute Hennrich and K. Kopka},
title = {Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy},
journal = {Pharmaceuticals},
year = {2019},
volume = {12},
publisher = {MDPI},
month = {jul},
url = {https://doi.org/10.3390/ph12030114},
number = {3},
pages = {114},
doi = {10.3390/ph12030114}
}
Cite this
MLA
Copy
Hennrich, Ute, et al. “Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy.” Pharmaceuticals, vol. 12, no. 3, Jul. 2019, p. 114. https://doi.org/10.3390/ph12030114.